115 related articles for article (PubMed ID: 38812296)
41. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis.
Lu YX; Ju HQ; Wang F; Chen LZ; Wu QN; Sheng H; Mo HY; Pan ZZ; Xie D; Kang TB; Chen G; Yun JP; Zeng ZL; Xu RH
Cancer Lett; 2016 Sep; 380(1):87-97. PubMed ID: 27322737
[TBL] [Abstract][Full Text] [Related]
42. Brexpiprazole suppresses cell proliferation and de novo lipogenesis through AMPK/SREBP1 pathway in colorectal cancer.
Li T; Liu X; Long X; Li Y; Xiang J; Lv Y; Zhao X; Shi S; Chen W
Environ Toxicol; 2023 Oct; 38(10):2352-2360. PubMed ID: 37347510
[TBL] [Abstract][Full Text] [Related]
43. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
[TBL] [Abstract][Full Text] [Related]
44. Lycorine inhibits cell proliferation, migration and invasion, and primarily exerts
Zhang P; Yuan X; Yu T; Huang H; Yang C; Zhang L; Yang S; Luo X; Luo J
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649853
[TBL] [Abstract][Full Text] [Related]
45. Naringin Inhibits Colorectal Carcinogenesis by Inhibiting Viability of Colorectal Cancer Cells.
Zeng JN; Tan JY; Mo L
Chin J Integr Med; 2023 Aug; 29(8):707-713. PubMed ID: 37340202
[TBL] [Abstract][Full Text] [Related]
46. MicroRNA-141-3p affected proliferation, chemosensitivity, migration and invasion of colorectal cancer cells by targeting EGFR.
Xing Y; Jing H; Zhang Y; Suo J; Qian M
Int J Biochem Cell Biol; 2020 Jan; 118():105643. PubMed ID: 31704502
[TBL] [Abstract][Full Text] [Related]
47. FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer.
Marzi L; Combes E; Vié N; Ayrolles-Torro A; Tosi D; Desigaud D; Perez-Gracia E; Larbouret C; Montagut C; Iglesias M; Jarlier M; Denis V; Linares LK; Lam EW; Martineau P; Del Rio M; Gongora C
Br J Cancer; 2016 Nov; 115(10):1223-1233. PubMed ID: 27685445
[TBL] [Abstract][Full Text] [Related]
48. Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin.
Narvi E; Vaparanta K; Karrila A; Chakroborty D; Knuutila S; Pulliainen A; Sundvall M; Elenius K
Sci Rep; 2018 Nov; 8(1):16579. PubMed ID: 30410004
[TBL] [Abstract][Full Text] [Related]
49. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
[TBL] [Abstract][Full Text] [Related]
50. Circular RNA circ_0007142 regulates cell proliferation, apoptosis, migration and invasion via miR-455-5p/SGK1 axis in colorectal cancer.
Wen T; Wu H; Zhang L; Li K; Xiao X; Zhang L; Zhang Y
Anticancer Drugs; 2021 Jan; 32(1):22-33. PubMed ID: 32889894
[TBL] [Abstract][Full Text] [Related]
51. Platycodin D represses β-catenin to suppress metastasis of cetuximab-treated KRAS wild-type colorectal cancer cells.
Lv Y; Wang W; Liu Y; Yi B; Chu T; Feng Z; Liu J; Wan X; Wang Y
Clin Exp Metastasis; 2023 Aug; 40(4):339-356. PubMed ID: 37326719
[TBL] [Abstract][Full Text] [Related]
52. Cetuximab enhances the anti-tumor function of macrophages in an IL-6 dependent manner.
Zhao Y; Liu X; Huo M; Wang Y; Li Y; Xu N; Zhu H
Life Sci; 2021 Feb; 267():118953. PubMed ID: 33359746
[TBL] [Abstract][Full Text] [Related]
53. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
54. Pien Tze Huang Inhibits Proliferation of Colorectal Cancer Cells through Suppressing PNO1 Expression and Activating p53/p21 Signaling Pathway.
Cao LJ; Liu LY; Chen YQ; Han YY; Wei LH; Yao MY; Fang Y; Wu MZ; Cheng Y; Sferra TJ; Liu HX; Li L; Peng J; Shen AL
Chin J Integr Med; 2024 Jun; 30(6):515-524. PubMed ID: 38216838
[TBL] [Abstract][Full Text] [Related]
55. Gracillin shows potent efficacy against colorectal cancer through inhibiting the STAT3 pathway.
Yang L; Zhu T; Ye H; Shen Y; Li Z; Chen L; Wang C; Chen X; Zhao H; Xiang Y; Xiao Z; Zhao C; Li J; Hu W
J Cell Mol Med; 2021 Jan; 25(2):801-812. PubMed ID: 33259114
[TBL] [Abstract][Full Text] [Related]
56. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
[TBL] [Abstract][Full Text] [Related]
57. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
[TBL] [Abstract][Full Text] [Related]
58. Cisatracurium regulates the CXCR4/let-7a-5p axis to inhibit colorectal cancer progression by suppressing TGF-β/SMAD2/3 signalling.
Xia YZ; Shan GF; Yang H; Zha J; Wang L; Chen JM; Zhang XS
Chem Biol Interact; 2021 Apr; 339():109424. PubMed ID: 33617803
[TBL] [Abstract][Full Text] [Related]
59. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
[TBL] [Abstract][Full Text] [Related]
60. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
